The Swiss IRB approved two new subjects for our LSD study (subjects #10 and #11) who have anxiety related to their disease which will likely reduce their lifespan, although their condition is not likely to be fatal in the next few years. The subjects suffer from Parkinson’s Disease and Bechterew’s Disease. Since this is an exploratory study, we’ve decided it is worthy of scientific investigation to accept a few subjects with major anxiety over a life-shortening disease, rather than a life-threatening disease. This will enable us to gather preliminary information about a broader range of potential subjects for future LSD-assisted psychotherapy research.
